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Abstract 
BACKGROUND: HER2 protein expression in gastric carcinoma, in correlation with existing, acknowledged 
prognostic factors which include the parameters that determine the TNM stage of the disease, could become the 
basis for ongoing research in the field of molecular targeted and personalised therapy. 
AIM: To determine the expression of the HER2 protein in gastric carcinoma and to correlate the expression of a 
HER2 protein with clinicopathological characteristics of the disease. 
MATERIAL AND METHODS: The data of HER2 protein expression and the parameters of the TNM classification 
were obtained from the histopathological reports of the Institute of Pathology in Skopje, and for the clinical stage 
we used patient’s files from the University Clinic for Abdominal Surgery in Skopje.  
RESULTS: The analysis of the correlation of HER2 protein expression and TNM classification parameters pointed 
out a significant correlation between HER2 protein expression and intragastric localisation of gastric carcinoma (P 
= 0.005), and the tumour grade of differentiation (P = 0.034). There was also a positive correlation between HER2 
protein expression pattern and positive lymph nodes in patients with gastric carcinoma (P = 0.03). The expression 
pattern of HER2 +++ was significantly more common registered in patients with positive lymph nodes (P = 0.03) 
CONCLUSION: The expression of HER2 protein could represent a biological marker with prognostic and 
predictive value in patients with gastric carcinoma. Considering the high mortality rate in patients with gastric 
carcinoma and lack of international standardised therapeutic approach, research of the role and significance of 
HER2 overexpression and Trastuzumab therapy may prove useful in the development of new therapeutic 
strategies. 
 
 
 
 
 
 
 
Introduction 
 
Gastric carcinoma is an aggressive disease 
that has a daunting impact on global health. Despite 
the decline in incidence and mortality rate in recent 
years, gastric carcinoma remains one of the leading 
causes of cancer-related deaths worldwide, especially 
in developing countries. According to the recent 
statistical database, gastric carcinoma, with 930,000 
new diagnosed and 700,000 diseased per year, is 
included with 8% out of 10% cancer-related deaths 
per year among the world population [1] [2] [3]. 
Because the most patients present with advanced 
disease the survival rate in patients with gastric 
carcinoma remains low, besides the evolution of new 
and sophisticated surgical techniques and the 
development of supplementary preoperative, 
neoadjuvant and adjuvant chemotherapy protocols. 
Recognition of complete recovery after surgical 
treatment is present only in early stages of diagnosed 
gastric carcinoma. According to the fact that, even in 
developed countries, primary detection of gastric 
carcinoma is in the nonresectable stadium of the 
disease, the systemic therapy is the main option for 
treatment that will only prolong the duration of survival 
[4] [5] [6]. In spite of the surgical treatment and 
systemic/adjuvant chemotherapy, survival rate in 
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patients with advanced stage of gastric carcinoma 
remains low, as a consequence of which the medical 
treatment of patients in advanced stage of gastric 
carcinoma demands novel therapeutic possibilities.  
Understanding the molecular basis of cancer 
will facilitate the development of novel molecular 
target therapies, which interfere with different signal 
cascades involved in cellular proliferation, 
differentiation and survival. For this purpose, new 
research reports for the influence of new biomarkers 
such as microRNA, microsatellite instability, different 
types of cytokines (IL1, IL6, IL10, IL11, TNF, X12), 
CyclinD, Bcl2, p53 and other, including the HER2 
protein in carcinogenesis, and as e target molecules 
for new therapeutic modalities are more often 
published [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 
[18]. 
The data about HER2 protein expression are 
dual, and the reported results in the literature are 
different, as a consequence of which the evaluation of 
HER2 protein expression values in gastric carcinoma 
in correlation with other clinicopathological prognostic 
factors is currently ongoing process [7] [15] [16] [17]. 
HER2 protein expression in gastric 
carcinoma, in correlation with existing acknowledged 
prognostic factors which include the parameters that 
determine the TNM stage of the disease, could 
become the basis for ongoing research in the field of 
molecular targeted and personalised therapy. 
This research aims to determine the 
correlation between tissue expression of the HER2 
protein and the stage of the disease, the parameters 
of TNM gastric carcinoma classification and the 
histologic grade of gastric cancer. 
 
 
Material and Methods 
 
One hundred and forty-nine patients with 
gastric carcinoma surgically treated at the University 
Clinic for abdominal surgery in Skopje were included 
in the study. The operative material was analysed at 
the Institute of Pathology, Medical Faculty in Skopje. 
Before the surgical treatment at the University 
Clinic for Abdominal Surgery in Skopje, an imaging 
technique procedure, gastroscopy and preoperative 
evaluation and preparation were obtained. For every 
patient, a standard operative procedure, according to 
the tumour localisation with loco-regional and 
systemic lymphadenectomy was performed. Sixty-one 
patients underwent subtotal gastric resection with 
lymphadenectomy, and 88 patients underwent total 
gastrectomy with lymphadenectomy.  
Following the surgical treatment, a 
substitution therapy in the post-operative period was 
applied, using different solutions. The substitution 
therapy includes correction of electrolyte disbalance 
with electrolyte solutions, correction of anaemia with 
transfusion, correction of hypoproteinemia with 
plasma and pure albumin solution, correction of 
coagulation factors deficiency with fresh frozen 
plasma and antibiotic therapy was performed if 
necessary. Every patient had a controlled 
postoperative dietary regime, antithrombotic 
prophylaxis and controlled analgesia for pain 
management. 
 
Figure 1: Immunohistochemical HER2 protein expression 
histological patterns. a) Her2+++ pattern of expression (х 200); b) 
same pattern of expression at higher magnification (х 400); c) Her2 
++ pattern of expression (x 400); d) Her2 + pattern of expression (x 
400) 
 
Data of HER2 protein expression and the 
parameters of the TNM classification (AJCC Cancer 
Staging 2017) were obtained from the archive 
histopathological reports of the Institute of Pathology 
in Skopje, and for the clinical stage, we used patient’s 
files from the University Clinic for Abdominal Surgery 
in Skopje.  
Immunohistochemical stainings were made 
with a standard procedure using Immunoperoxidase 
LSAB + system and specific primary monoclonal 
HER2-antibody (Ventana Medical Systems, Roche, 
and-HER2/neu Rabbit Monoclonal Primary Antibody 
Clone 4B5). 
HER2 protein overexpression was defined in 
4 histological patterns [18] (Figure 1): 
0 No membranous staining or staining of < 
10% of the tumour cells  
+ Staining is weak or detected in only one part 
of the membrane in ≥ 10% of the cells  
++ Moderate/weak complete or basolateral 
membranous staining in ≥ 10% of the cells  
+++ Strong complete or basolateral 
membranous staining in ≥ 10% of the neoplastic cells  
HER2 ++ and + expression are additionally 
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determined with Fluorescent in Situ Hybridization 
(FISH) method  
To make a correlation between tissue HER2 
protein expression and the disease stage, parameters 
of the TNM classification and histologic tumour grade 
HER2 expression was carried out in 2 steps. The first 
step, the patients were divided into two groups, 
according to the HER2 protein expression, as patients 
with positive HER2 expression and patients with 
negative HER2 immunostaining, excluding the 
importance of protein expression scheme. In the 
second step, the same analyses were repeated, 
except for the fact that HER2 positivity was analysed 
according to the scheme mentioned above (+, ++, 
+++). 
Descriptive statistical methods were used for 
statistical analysis of the data. The rate of the 
interdependence of the analysed parameters was 
obtained with linear correlation. Statistical program 
SPSS for Windows 19.0 was used. 
 
 
Results 
 
The analysed group consisted of 149 patients, 
with the mean age of 65.19 ± 10.1, 108 (72.48%) of 
which were female and 41 (27.52%) male. 
Clinical and histopathological characteristics 
of the patients and their cancers are shown in Table 1. 
Table 1: Clinical and pathological characteristics of the 
analysed patients 
Parameter N (%) 
Localization  
Cardia 61 (40.94) 
Corpus 37 (24.83) 
Antrum/Pylorus 51 (34.23) 
T  
1 5 (3.6) 
2 19 (12.75) 
3 41 (27.52) 
4 84 (56.38) 
Nodal involvement  
Negative 36 (24.16) 
Positive 113 (75.84) 
Nodal status (TNM classification)  
0 36 (24.16) 
1 27 (18.12) 
2 30 (20.13) 
3 56 (37.58) 
Distant metastases  
No 136 (91.27) 
Yes 13 (8.72) 
Grade  
1 2.68) 
2 64 (42.95) 
3 81 (54.36) 
Stage  
I 11 (7.38) 
II 37 (24.83) 
III 88 (59.06) 
IV 13 (8.72) 
 
The most common intragastric location of 
gastric carcinomas was cardia in 61 (40.94%) 
patients, followed by antral/pyloric carcinoma location 
in 51 (34.23%) patients and corpus location in 37 
(24.83%) patients. According to the T state (local 
tumour growth), more than half of the examined 
patients 84 (56.38%) were in T4 state of the disease. 
Presence of positive regional lymph nodes 
was detected in 113 (75.84) patients, and negative in 
36 (24.16%) patients. The majority of the patients that 
comprised the analysed group had poor differentiated 
gastric carcinoma 81 (54.36%), and 88 (59.06%) were 
in Stage III of the disease. 
Immunohistochemical staining with HER2 
antibody showed HER2 protein expression in 44 
(29.53%) carcinoma tissue, of which (6.71%) with 
HER2+, 7 (4.69%) with HER2++ and 27 (18.12%) with 
HER2+++ expression pattern. 
Table 2: HER2 expression in analyzed patients 
Variable N (%) 
Her2 expression (pattern) 
- 105 (70.47) 
+ 10 (6.71) 
++ 7 (4.69) 
+++ 27 (18.12) 
Her2 positivity 
Negative cases 105 (70.47) 
Positive cases 44 (29.53) 
 
HER2 + expression pattern in gastric 
carcinoma was more frequent in female patients 
(27.59% vs 13.33%), while HER2+++ expression 
pattern was more frequently represented in male 
patients (73.33% vs 55.17%) in the group of 44 
positive cases. 
There was the insignificant difference in the 
distribution of HER2 protein expression according to 
the gender of the patients (P = 0.4). 
Patients with positive HER2 protein 
expression in gastric carcinoma were with a median 
age of 65.5 ± 9.8 years, and patients with no HER2 
protein expression were with a median age of 64.4 ± 
10.7 years, without significant difference between the 
groups (P = 0.55). 
Presence of HER2 protein was obtained in 16 
(26.23%) carcinomas with a location in gastric cardia, 
11 (29.735) in the corpus and 17 (33.33%) 
carcinomas with the antral/pyloric location, with no 
significant difference in HER2 protein expression, 
according to the location of gastric carcinoma (P = 
0.71). 
The analysis of different HER2 expression 
patterns showed: 
HER2+ protein was more frequently present 
in gastric carcinomas with a location in the corpus 
(54.55%) about antrum/pylorus location (17.65%) and 
cardia (6.25%). 
HER2++ expression was most frequently 
registered in carcinomas located in cardia (31.25%) 
and was absent in gastric corpus. 
HER2+++ protein expression was more 
frequent in antral/pyloric location, in correlation with 
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cardia and corpus location (70.59%, 62.5%, 45.45% 
respectively). 
Statistical analysis confirmed the presence of 
a significant difference in HER2 protein expression 
pattern according to the location of the gastric 
neoplasm (Table 3). 
Table 3: HER2 protein expression in gastric carcinoma 
according to the location 
Localization n Her2 expression pattern P-value 
  + ++ +++  
Cardia 61 1 (6.25) 5 (31.25) 10 (62.50) 0.005** 
Corpus 37 6 (54.55) 0 5 (45.45) 
Antrum/Pylorus 51 3 (17.65) 2 (11.76) 12 (70.59) 
*P < 0.05; **P < 0.01. 
 
We did not find significant differentiation in 
HER2 expression according to the local growth (T 
status) neither when analysed only HER2 negative 
cases with HER2 positive, nor when we analysed 
HER2 negative carcinomas with different HER2 
positive patterns (+,++,+++) (P = 0.54, P = 0.63 
respectively. 
HER2 protein expression was insignificantly 
different in patients with gastric carcinoma with 
positive and negative lymph nodes. Additional 
analysis of different HER2 expression pattern 
regarding positive and negative lymph nodes showed 
that HER2 +++ was significantly more frequent in 
patients with positive regional lymph nodes (P = 0.03). 
HER2 +++ pattern was found in 33.33% of patients 
with negative lymph nodes and 68.57% of patients 
with positive lymph nodes. 
Statistically, a significant difference was found 
in the carcinomas with different grade (G) in patients 
with positive and negative HER2 expression. More 
frequent HER2 expression was detected in patients 
with moderately differentiated carcinomas in 
comparison to the patients with poorly differentiated 
carcinomas (40.63% vs 20.99%, P = 0.034), (Table 4). 
Table 4: Distribution of HER and HER negative patients 
according to the grade of carcinoma differentiation 
Grade n Her2 expression p-value 
  Negative Positive  
G1 4 3 (75) 1 (25) 0.034 
G2 64 38 (59.38) 26 (40.63) 
G3 81 64 (79.01) 17 (20.99) 
*P < 0.05; **P < 0.01. 
 
Additional analysis of HER2 expression 
patterns (+, ++, +++) confirmed non-significant 
difference in HER2 expression patterns according to 
the tumor differentiation (P = 0.28), but there was a 
statistically negative significant correlation between 
HER2 expression pattern and tumor differentiation (P 
= 0.01), meaning that HER2+++ pattern was 
significantly related to well-differentiated carcinomas 
(Figure 2). 
 
Figure 2: Correlation between the grade of differentiation and HER2 
protein expression 
 
HER2 protein expression was not significantly 
related to the Stage of the disease neither an analysis 
of positive and negative cases nor in HER2 
expression patterns analysis (P = 0.56; P = 0.61, 
respectively). 
 
 
Discussion 
 
TNM classification of gastric carcinoma is the 
most valuable prognostic factor in patients with this 
disease. The classification contains the following 
elements: T – local tumour growth, N- lymph node 
involvement and M- the distant metastatic spread of 
the primary disease. The grade of differentiation of a 
tumour is also a part of the classification. However, 
there is a variable prognosis among the patients at the 
equal stage of the disease. Therefore, a request for 
revealing additional parameters for better identification 
of biological subgroups imposes itself. Biological 
predictive factors are obtained from genetic process, 
which is considered to be the key step in the 
development of gastric carcinoma (HER2, E-cadherin, 
EGFR, microsatellite instability, changes in few factor 
expression, including thymidylate synthase, beta-
catenin, mucin-Ag, p53, COX-2, matrix 
metalloproteinases, and receptors for vascular 
endothelial factor) [7]. 
HER2 protein (HER2/neu, ErbB-2) is a 185-
kDa transmembrane tyrosine kinase receptor, coded 
by HER2 proto-oncogene, located on the long arm of 
the 17-the chromosome. HER2 protein is a member of 
epidermal growth factor receptor family. This receptor 
family consists of 4 members: HER1 (also known as 
EGFR), HER2 (ErbB2), HER3 (ErbB3) and HER4 
(ErbB4), which share the same molecular structure on 
their extracellular domain for ligand binding and 
intracellular part with tyrosine-kinase (TK) activity 
(with the exception of HER3). HER2 does not bind to 
anyone knew ligand and is considered to be ligand-
free co-receptor for all other members of ErbB family. 
In fact, HER2 presents a peripheral partner for hetero-
dimerisation of other members of HER family. Ligand 
binding to HER family cellular receptor induces homo-
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dimerisation and hetero-dimerisation of EGFR to other 
types of HER proteins (HER2 is a part of the hetero-
dimerisation process). Various ligand binding activity 
for extracellular domain initiates a signal transmitting 
(transducing) cascade, which may have an impact on 
the cell proliferation, apoptosis, cell adhesion, 
migration, angiogenesis and differentiation [7] [8] [9] 
[19] [20]. 
Many authors suggest an important HER2 
role in various cancer types development. HER2 
expression and/or amplification is recorded in invasive 
type of breast carcinoma [19], endocrine cancer [20] 
colon carcinoma [21], bladder carcinoma [22], ovarian 
carcinoma [23], endometrial [24] and cervical 
carcinoma [25], lung carcinoma [26], head and neck 
carcinoma [27], esophageal [28] and gastric 
carcinoma [29].  
The reported data about the overexpression 
of HER2 in gastric carcinoma are diverse, depending 
on characteristics of the analysed groups and HER2 
overexpression is reported in a range from 2% to 
34%. The difference in expression is dependent on 
the localisation of a tumour in the stomach 
(gastroesophageal function or other localisation), the 
histological subtype (diffuse, intestinal, mixed, and 
unknown), and differentiation of a tumour. 
Although according to some authors, there is 
no correlation between over-expression of HER2 and 
the disease prognosis, other authors found an 
association between HER2 overexpression and worse 
prognosis. It is considered that HER2 expression is in 
positive correlation with the tumor size, serous 
invasion and lymph node metastases, and also with 
poor prognosis of the patients for the 10-year survival 
period [7] [14] [29] [30] [31] [32] [33] [34] [35] [36). 
The results from this study confirmed a 
significant correlation between tissue expression of 
HER2 and intragastric tumour location, lymph node 
metastasis and grade of tumour differentiation. The 
correlation between HER2 expression and the grade 
of differentiation is determined as negative, which 
means that HER2 expression is significantly 
associated with the more differentiated carcinomas, 
i.e. well-differentiated carcinomas.  
Trastuzumab (Herceptin, Genentech, San 
Francisco, CA), is a monoclonal antibody that 
interferes with HER2 receptor (EGFR 2 receptor 
blocker), which in combination with chemotherapy 
protocols improves the outcome and survival in 
patients with different types of carcinomas, including 
the gastric carcinoma [19] [37] [38], but yet some 
patient may develop resistance to therapy with this 
antibody. For that reason, ongoing research on HER2 
receptor are still required [38] The results from The 
International randomized study carried out in 2010, 
(Trastuzumab for gastric cancer treatment), revealed 
that Herceptin human monoclonal antibody, 
trastuzumab antibody anti-HER2 significantly prolong 
the overall survival, in comparison to chemotherapy 
protocol alone, in patients with HER2 overexpression 
[20] [37] [38] [39]. So, this research may be the basis 
for continuous research of the importance of HER2 
expression in gastric carcinoma, with scientific and 
also medical call practice contribution.  
In conclusion, this research determined 
significant difference in HER2 expression in gastric 
carcinoma with antro/pyloric localiztion, in comparison 
to carcinoma located on gastric cardia or corpus.  
Statistically significant negative correlation of 
HER2 expression in gastric carcinoma and histologic 
grade of a tumour is also cinfirmed. According to 
these results, HER2 expression is significantly 
corelated to more aggressive disease and possibility 
of poor outcome. 
We also found significant correlation between 
HER2 expression pattern HER2+++ and metastasis in 
regional lymph nodes.  
The correlation of HER2 expression and 
above mentioned parameters highlights the possibility 
of HER2 expression being a valuable biologic marker 
with prognostic importance in gastric carcinoma 
patients. Considering the high mortality rate in 
patients with gastric carcinoma and lack of 
international standardized therapeutic approach, 
research of the role and significance of HER2 
overexpression and Transtuzumab therapy may prove 
useful in development of new therapeutic strategies 
and treatment possibilities. 
  
 
References 
 
1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. 
CA Cancer J Clin. 2005; 55:74–108. 
https://doi.org/10.3322/canjclin.55.2.74 PMid:15761078  
2. Lee HE, Chae SW, Lee YJ, et al. Prognostic implications of type 
and density of tumour-infiltrating lymphocytes in gastric cancer. 
BJC. 2008; 99:1704–11. https://doi.org/10.1038/sj.bjc.6604738 
PMid:18941457 PMCid:PMC2584941 
 
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA 
Cancer J Clin. 2011; 61:69 90. https://doi.org/10.3322/caac.20107 
PMid:21296855  
 
4. Cunningham D, Allum WH, Stenning SP, et al. Perioperative 
chemotherapy versussurgery alone for resectable 
gastroesophageal cancer. New Eng J Med. 2006; 355(1):11–22. 
https://doi.org/10.1056/NEJMoa055531 PMid:16822992  
 
5. Macdonald JS, Smalley SR, Benedetti J, et al. 
Chemoradiotherapy after surgerycompared with surgery alone for 
adenocarcinoma of the stomach or gastroesophageal junction. N 
Eng J Med. 2001; 345(10):725–30. 
https://doi.org/10.1056/NEJMoa010187 PMid:11547741  
 
6. Sastre J, García-Saenz JA, Díaz-Rubio E. Chemotherapy for 
gastric cancer. World journal of gastroenterology: WJG. 2006; 
12(2):204. https://doi.org/10.3748/wjg.v12.i2.204 PMid:16482619 
PMCid:PMC4066028 
 
7. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic 
factor and a novel therapeutic target. Annals of Oncology. 2008; 
19:1523–29. https://doi.org/10.1093/annonc/mdn169 
 
Basic Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
1192                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
PMid:18441328  
8. Zhou F, Li N, Jiang W, et al. Prognosis significance of HER 
2/neu overexpression/amplification in Chinese patients with 
curatively resected gastric cancer after the ToGA clinical trial. 
World J Surg Oncol. 2012; 10:274. https://doi.org/10.1186/1477-
7819-10-274 PMid:23249720 PMCid:PMC3579675 
 
9. Jin Z, Jiang W, Wang L. Biomarkers for gastric cancer: 
Progression in early diagnosis and prognosis (Review). Oncology 
Letters. 2015; 9:1502-08. https://doi.org/10.3892/ol.2015.2959 
PMid:25788990 PMCid:PMC4356326 
 
10. Bazley LA, Gullick WJ. The epidermal growth factor receptor 
family. Endocrine-Related Cancer. 2005; 12:S17–S27. 
https://doi.org/10.1677/erc.1.01032 PMid:16113093  
 
11. Schuell B, Gruenberger T, Scheithauer W, et al. HER 2/neu 
protein expression in colorectal cancer. BMC Cancer. 2006; 
8(6):123. https://doi.org/10.1186/1471-2407-6-123 PMid:16681853 
PMCid:PMC1475876 
 
12. Eltze E, Wulfing C, Von Struensee D, et al. Cox-2 and 
Her2/neu co-expression in invasive bladder cancer. Int J Oncol. 
2005; 26(6):1525–1531. https://doi.org/10.3892/ijo.26.6.1525 
 
13. McKenzie SJ, DeSombre KA, Bast BS, et al. Serum levels of 
HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in 
human ovarian cancer. Cancer. 1993; 71:3942–6. 
https://doi.org/10.1002/1097-0142(19930615)71:12<3942::AID-
CNCR2820711224>3.0.CO;2-3 
 
14. Hetzel DJ, Wilson TO, Keeney GL, et al. HER-2/neu 
expression: a major prognostic factor in endometrial cancer. 
Gynecol Oncol. 1992; 47:179–85. https://doi.org/10.1016/0090-
8258(92)90103-P 
 
15. Hirashima N, Takahashi W, Yoshii S, et al. Protein 
overexpression and gene amplification of c-erb B-2 in pulmonary 
carcinomas: a comparative immunohistochemical and fluorescence 
in situ hybridization study. Mod Pathol. 2001; 14:556–662. 
https://doi.org/10.1038/modpathol.3880350 PMid:11406656  
 
16. Mitra AB, Murty VVS, Pratap M, et al. ERBB2 (HER2/neu) 
oncogene is frequently amplified in squamous cell carcinoma of the 
uterine cervix. Cancer Res. 1994; 54:637–9. PMid:7905784  
 
17. Beckhardt RN, Kiyokawa N, Xi L, et al. HER-2/neu oncogene 
characterization in head and neck squamous cell carcinoma. Arch 
Otolaryngol Head Neck Surg. 1995; 121(11):1265–70. 
https://doi.org/10.1001/archotol.1995.01890110041008 
PMid:7576473  
 
18. Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in 
gastric cancer: An update. World J Gastroenterol. 2016; 
22(19):4619-4625. https://doi.org/10.3748/wjg.v22.i19.4619 
PMid:27217694 PMCid:PMC4870069 
 
19. Lordick F, Bang YJ, Kang YK, et al. HER2-positive advanced 
gastric cancer: similar HER2-positivity levels to breast cancer. Eur 
J Cancer. 2007; 5(4):271. 
 
20. Kang Y, Bang Y, Lordick F, et al. Incidence of gastric and 
gastro-esophageal cancer in the ToGA trial: correlation with HER2 
positivity. Gastrointestinal Cancers Symposium. 2008: 75(Abstr 
11). 
 
21. Tateishi M, Toda T, Minamisono Y, et al. Clinicopathological 
significance of c-erbB-2 protein expression in human gastric 
carcinoma. Surg Oncol. 1992; 49:209–212. 
https://doi.org/10.1002/jso.2930490402 
 
22. Sasano H, Date F, Imatani A, et al. Double immunostaining for 
c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol. 
1993; 24:584–9. https://doi.org/10.1016/0046-8177(93)90236-A 
 
23. Uchino S, Tsuda H, Maruyama K, et al. Overexpression of c-
erbB-2 protein in gastric cancer. Its correlation with long-term 
survival of patients. Cancer. 1993; 72:3179–184. 
https://doi.org/10.1002/1097-0142(19931201)72:11<3179::AID-
CNCR2820721108>3.0.CO;2-# 
 
24. Mizutani T, Onda M, Tokunaga A, et al. Relationship of c-erbB-
2 protein expression and gene amplification to invasion and 
metastasis in human gastric cancer. Cancer. 1993; 72:2083–8. 
 
https://doi.org/10.1002/1097-0142(19931001)72:7<2083::AID-
CNCR2820720705>3.0.CO;2-1 
25. Nakajima M, Sawada H, Yamada Y, et al. The prognostic 
significance of amplification and overexpression of c-met and c-
erbB-2 in human gastric carcinomas. Cancer. 1999; 85:1894–1902. 
https://doi.org/10.1002/(SICI)1097-
0142(19990501)85:9<1894::AID-CNCR3>3.0.CO;2-J 
 
26. Yamanaka S, Olaru AV, An F, et al. MicroRNA 21 inhibits 
Serpini1, a gene with novel tumour suppressive effects in gastric 
cancer. Dig Liver Dis. 2012; 44:589 96. 
https://doi.org/10.1016/j.dld.2012.02.016 PMid:22464652 
PMCid:PMC3360813 
 
27. Hudler P. Genetic aspects of gastric cancer instability. 
Scientific World Journal. 2012; 2012: 761909. 
https://doi.org/10.1100/2012/761909 PMid:22606061 
PMCid:PMC3353315 
 
28. Yasui W, Sumiyoshi H, Hata J, et al. Expression of epidermal 
growth factor receptor in human gastric and colonic carcinomas. 
Cancer Res. 1988; 48:137 41. 
 
29. Sakai K, Mori S, Kawamoto T, et al. Expression of epidermal 
growth factor receptors on normal human gastric epithelia and 
gastric carcinomas. J Natl Cancer Inst. 1986; 77:1047 1052. 
PMid:3464796  
 
30. Garcia I, Vizoso F, Martin A, et al. Clinical significance of the 
epidermal growth factor receptor and HER2 receptor in resectable 
gastric cancer. Ann Surg Oncol. 2003; 10:234 241. 
https://doi.org/10.1245/ASO.2003.05.010 PMid:12679307  
 
31. Terashima M, Kitada K, Ochiai A, et al. ACTS GC Group: 
Impact of expression of human epidermal growth factor receptors 
EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin 
Cancer Res. 2012; 18:5992 6000. https://doi.org/10.1158/1078-
0432.CCR-12-1318 PMid:22977193  
 
32. Kono K, Takahashi A, Sugai H, at al. Dendritic Cells Pulsed 
with HER-2/neu-derived Peptides Can Induce Specific T-Cell 
Responses in Patients with Gastric Cancer. Clin Cancer Res. 
2002; 8:3394–400. PMid:12429626  
 
33. Kim JY, Jeon TJ, Bae BN, et al. The prognostic significance of 
growth factors and growth factor receptors in gastric 
adenocar¬cinoma. APMIS. 2013; 121:95 104. 
https://doi.org/10.1111/j.1600-0463.2012.02942.x PMid:23030255  
 
34. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 
scoring system for gastric cancer: results from a validation study. 
Histopathology. 2008; 52(7):797-805. 
https://doi.org/10.1111/j.1365-2559.2008.03028.x PMid:18422971  
 
35. Mitri Z, Constantine T, O'Regan R. The HER2 Receptor in 
Breast Cancer: Pathophysiology, Clinical Use, and New Advances 
in Therapy. Chemother Res Pract. 2012; 2012:743193. 
https://doi.org/10.1155/2012/743193 
 
36. Reichelt U, Duesedau P, Tsourlakis MCh, et al. Frequent 
homogenous HER-2 amplification in primary and metastatic 
adenocarcinomas of the esophagus. Mod Path. 2007; 20(1):120–
129. https://doi.org/10.1038/modpathol.3800712 PMid:17143264  
 
37. Gravalos C, Marquez A, Garcia-Carbonero R, et al. Correlation 
between Her2/neu overexpression/amplification and 
clinicopathological parameters in advanced gastric cancer patients: 
a prospective study. Gastrointestinal Cancers Symposium, 
2007:130 (Abstr 89). 
 
38. Fujimoto-Ouci K, Sekiguchi F, Yasuno H, Moriya Y, Moti K, 
Tanaka Y. Antitumor activity of transtuzumab in combination with 
chemotherapy in human gastric cancer xenograft models. Cancer 
Chemotherapy and Pharmacology. 2007; 59(6):795-805. 
https://doi.org/10.1007/s00280-006-0337-z PMid:17031648  
 
39. Zuo Q, Liu J, Zhang J, Wu M, Guo L, Liao W. Development of 
trastuzumab-resistant human gastric carcinoma cell lines and 
mechanisms of drug resistance. Scientific reports. 2015; 5:11634. 
https://doi.org/10.1038/srep11634 PMid:26108989 
PMCid:PMC4479993 
 
 
